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Clinics and pathology 
Disease 
Peripheral T-cell lymphomas not otherwise specified 
(PTCL-NOS) include a heterogeneous group of 
diseases involving lymph nodes and extra nodal sites 
deriving from the clonal expansion of mature T-
lymphocytes bearing clonally rearranged TCR genes. 
Phenotype/cell stem origin 
The cell of origin is an activated mature CD4+ 
lymphocyte. 
The phenotype is usually CD4+/CD8-, TCRβ+ whereas 
the expression of CD7 and CD5 may be low. 
Occasionally, CD30 may be positive. 
Epidemiology 
There is geographic variation in the incidence of T-cell 
lymphoma. PTCL-NOS accounts for approximately 4-
7% of all non Hodgkin's lymphomas and for 30-70% of 
all mature T-cell lymphomas. 
Clinics 
The disease runs an aggressive clinical course. 
Pathology 
The proliferation effaces the lymph node architecture, 
with paracortical or diffuse growth pattern. The cells 
are medium-to-large sized, with irregular nucleus, 
distinct nucleoli. Mitotic figures may be numerous. 
Treatment 
Anthracycline-based regimes such as CHOP yields  
unsatisfactory results with lower CR rates than in B-
cell diffuse large cell lymphomas and high relapse rat .  
Intensive regimens such as hyperCVAD with or 
without autologus bone marrow transplantation may be 
effective in this type of lymphoma, though the 
superiority of this approach over conventional 
treatment has not been definitely proven. 
Prognosis 
Reported failure free survival rates ranged between 12 
and 45% (Armitage, 2006). 
Cytogenetics 
Cytogenetics molecular 
Complex karyotypes are reported in 70-90% of the 
cases (Rizvi et al., 2006). 
Recurrent chromosome gains were described to involve 
7q, 8q, 17q and 22q, whereas recurrent regions of loss 
of chromosome material were represented at 4q, 5q, 6q, 
9p, 10q, 12q and 13q (Pileri et al., 2008). 
In a recent study, frequent gains involved 7q22q31 
(33%), 1q (24%), 3p (20%), 5p (20%) and 8q24qter 
(22%). Losses occurred at 6q22q24 (26%) and 
10p13pter (26%). 
Complex karyotypes were predictive of an inferior 
outcome, but no association was noted between specific 
aberrations and survival (Nelson et al., 2008). 
Array comparative genomic hybridization (CGH) for 
high-resolution analysis of PTCL-NOS identified a 
region with high copy number gain at 14q32.2, and a 
region with homozygous loss at 9p21.3. Gains of 7p 
and 7q and loss of 9p21.3 showed a significant 
association with poor prognosis (Nakagawa et al., 
2009). 
p53 protein overexpression and mutation of p53 may be 
found in 30% of the cases and may correlate 
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significantly with treatment failure and worse overall 
and disease-free survival (Pescarmona et al., 2001). 
Recurrent copy number gain may also involve 
chromosomes 8, 9 and 19. Other genomic imbalances 
may include overexpression of CARMA1 at 7p22 and 
of MYCBP2 at 13q22, both genes being localized 
within regions of frequent copy number gain. 
LOH was found at 2q34 (Fujiwara et al., 2008). 
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